431 reports of this reaction
3.2% of all EMTRICITABINE reports
#4 most reported adverse reaction
DRUG RESISTANCE is the #4 most commonly reported adverse reaction for EMTRICITABINE, manufactured by Gilead Sciences, Inc.. There are 431 FDA adverse event reports linking EMTRICITABINE to DRUG RESISTANCE. This represents approximately 3.2% of all 13,674 adverse event reports for this drug.
Patients taking EMTRICITABINE who experience drug resistance should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG RESISTANCE is moderately reported among EMTRICITABINE users, representing a notable but not dominant share of adverse events.
In addition to drug resistance, the following adverse reactions have been reported for EMTRICITABINE:
The following drugs have also been linked to drug resistance in FDA adverse event reports:
DRUG RESISTANCE has been reported as an adverse event in 431 FDA reports for EMTRICITABINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG RESISTANCE accounts for approximately 3.2% of all adverse event reports for EMTRICITABINE, making it a notable side effect.
If you experience drug resistance while taking EMTRICITABINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.